Figure-1 (Figure 1)
Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-3005
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-3005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-2 (Figure 2)
This document provides information about the effects of CYP3A4 inhibitors and inducers on drug metabolism, specifically focusing on Ketoconazole and Fluconazole as inhibitors, and Rifampin and Efavirenz as inducers. Additionally, it discusses the impact of these inhibitors and inducers on drugs such as Oral Methylphenidate and Lisdexamfetamine Dimesylate in terms of PK parameters like AUC (Area Under the Curve). The text also mentions Fold Change and 90% Confidence Interval in relation to these drug interactions.*
Figure-3 (Figure 3)
Figure4.jpg (Figure4)
Label (Lbl713353005)
This is a package insert for guanfacine hydrochloride tablets containing 4 mg of Guanfacine. The usual dosage information can be found by scanning the QR code on the package insert. The tablets are extended-release and should not be crushed, chewed, or broken before swallowing. The medication should be stored at 20° to 25°C with excursions permitted to 15° to 30°C. The tablets should be protected from moisture and dispensed in a tight container.*
Spd503-chemical-stucture (Spd503 Chemical Stucture)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
